HRP20120639T1 - Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola - Google Patents

Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola Download PDF

Info

Publication number
HRP20120639T1
HRP20120639T1 HRP20120639TT HRP20120639T HRP20120639T1 HR P20120639 T1 HRP20120639 T1 HR P20120639T1 HR P20120639T T HRP20120639T T HR P20120639TT HR P20120639 T HRP20120639 T HR P20120639T HR P20120639 T1 HRP20120639 T1 HR P20120639T1
Authority
HR
Croatia
Prior art keywords
compound
beta
mixture obtained
wetting agent
alpha
Prior art date
Application number
HRP20120639TT
Other languages
English (en)
Croatian (hr)
Inventor
Fran�ois Alexandre Lucas Hegyi Jean
Albert Alex Aelterman Wim
Lydia Lang Yolande
Carl Sigrid
Leys Carina
Jozef Maria Van Remoortere Peter
Faure Anne
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120639(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20120639T1 publication Critical patent/HRP20120639T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
HRP20120639TT 2006-12-05 2007-12-03 Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola HRP20120639T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
HRP20120639T1 true HRP20120639T1 (hr) 2012-08-31

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120639TT HRP20120639T1 (hr) 2006-12-05 2007-12-03 Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola

Country Status (34)

Country Link
US (1) US8546428B2 (cg-RX-API-DMAC7.html)
EP (1) EP2086940B1 (cg-RX-API-DMAC7.html)
JP (2) JP2010511663A (cg-RX-API-DMAC7.html)
KR (1) KR101514700B1 (cg-RX-API-DMAC7.html)
CN (2) CN105012303A (cg-RX-API-DMAC7.html)
AP (1) AP2498A (cg-RX-API-DMAC7.html)
AR (1) AR064149A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007328945B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719693A2 (cg-RX-API-DMAC7.html)
CA (1) CA2668512C (cg-RX-API-DMAC7.html)
CL (1) CL2007003472A1 (cg-RX-API-DMAC7.html)
CY (1) CY1113594T1 (cg-RX-API-DMAC7.html)
DK (1) DK2086940T3 (cg-RX-API-DMAC7.html)
EA (1) EA017091B9 (cg-RX-API-DMAC7.html)
ES (1) ES2387923T3 (cg-RX-API-DMAC7.html)
HK (1) HK1214513A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20120639T1 (cg-RX-API-DMAC7.html)
IL (1) IL199077A (cg-RX-API-DMAC7.html)
JO (1) JO2973B1 (cg-RX-API-DMAC7.html)
ME (1) ME01456B (cg-RX-API-DMAC7.html)
MX (1) MX2009005909A (cg-RX-API-DMAC7.html)
MY (1) MY148844A (cg-RX-API-DMAC7.html)
NO (1) NO342773B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ576485A (cg-RX-API-DMAC7.html)
PE (1) PE20081350A1 (cg-RX-API-DMAC7.html)
PL (1) PL2086940T3 (cg-RX-API-DMAC7.html)
PT (1) PT2086940E (cg-RX-API-DMAC7.html)
RS (1) RS52408B (cg-RX-API-DMAC7.html)
SI (1) SI2086940T1 (cg-RX-API-DMAC7.html)
TW (1) TWI417098B (cg-RX-API-DMAC7.html)
UA (1) UA97813C2 (cg-RX-API-DMAC7.html)
UY (1) UY30762A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008068231A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200903907B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) * 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
UA126891C2 (uk) * 2015-01-27 2023-02-22 Янссен Фармацевтика Нв Здатні до диспергування композиції
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) * 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
RU2018111482A (ru) * 2015-10-20 2019-11-21 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Кристаллические формы бедаквилин фумарата и способы их получения
EA202190285A1 (ru) * 2016-07-20 2021-08-31 Новартис Аг Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
ES2891976T3 (es) 2017-07-14 2022-02-01 Janssen Pharmaceutica Nv Formulaciones a largo plazo
WO2020123336A1 (en) * 2018-12-13 2020-06-18 Qrumpharma Inc. Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them
WO2020144197A1 (en) 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
EP4243800A1 (en) 2020-11-12 2023-09-20 JANSSEN Pharmaceutica NV Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
CA2270123A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
CA2219070C (en) * 1996-10-30 2007-12-18 Eli Lilly And Company Methods of preventing breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
JP4484703B2 (ja) * 2002-07-25 2010-06-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AU2005249231B2 (en) * 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EA009779B1 (ru) * 2004-12-24 2008-04-28 Янссен Фармацевтика Н.В. Лечение латентного туберкулёза

Also Published As

Publication number Publication date
EA017091B1 (ru) 2012-09-28
EA017091B9 (ru) 2014-10-30
NO342773B1 (no) 2018-08-06
AU2007328945B2 (en) 2014-04-03
TWI417098B (zh) 2013-12-01
CN105012303A (zh) 2015-11-04
JO2973B1 (en) 2016-03-15
AP2009004870A0 (en) 2009-06-30
NO20092535L (no) 2009-08-06
WO2008068231A1 (en) 2008-06-12
EP2086940A1 (en) 2009-08-12
IL199077A (en) 2016-09-29
ME01456B (me) 2014-04-20
SI2086940T1 (sl) 2012-09-28
HK1214513A1 (zh) 2016-07-29
AP2498A (en) 2012-10-19
DK2086940T3 (da) 2012-08-20
ZA200903907B (en) 2013-08-28
TW200838527A (en) 2008-10-01
CL2007003472A1 (es) 2008-08-22
PL2086940T3 (pl) 2012-10-31
CY1113594T1 (el) 2016-06-22
MX2009005909A (es) 2009-06-16
CA2668512A1 (en) 2008-06-12
NZ576485A (en) 2012-01-12
EA200970532A1 (ru) 2009-10-30
AR064149A1 (es) 2009-03-18
RS52408B (sr) 2013-02-28
KR101514700B1 (ko) 2015-04-24
JP2015028049A (ja) 2015-02-12
BRPI0719693A2 (pt) 2013-12-24
US20100028428A1 (en) 2010-02-04
JP5894239B2 (ja) 2016-03-23
CA2668512C (en) 2015-03-24
PT2086940E (pt) 2012-08-09
MY148844A (en) 2013-06-14
US8546428B2 (en) 2013-10-01
AU2007328945A1 (en) 2008-06-12
EP2086940B1 (en) 2012-05-16
CN101547904A (zh) 2009-09-30
ES2387923T3 (es) 2012-10-04
UY30762A1 (es) 2008-07-03
UA97813C2 (uk) 2012-03-26
KR20090087020A (ko) 2009-08-14
PE20081350A1 (es) 2008-09-18
JP2010511663A (ja) 2010-04-15

Similar Documents

Publication Publication Date Title
HRP20120639T1 (hr) Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
JP2010511663A5 (cg-RX-API-DMAC7.html)
KR101573889B1 (ko) 속효성과 지속성을 동시에 갖는 약제학적 조성물
AU2013318182B2 (en) Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP2009545560A5 (cg-RX-API-DMAC7.html)
TW200413006A (en) Solid dispersions comprising a hygroscopic and/or deliquescent drug
SI2659881T1 (en) Formulation of the delayed release medicinal product
CN102895208A (zh) 包衣片制剂和方法
JP2008520736A5 (cg-RX-API-DMAC7.html)
EP2018157A2 (en) Controlled release formulation comprising anti-epileptic drugs
JP5881700B2 (ja) ブロナンセリン経口放出制御型医薬組成物
WO2013058450A1 (ko) 안정화된 에페리손 의약 조성물 및 이를 함유하는 서방성 제제
JP2020536953A5 (cg-RX-API-DMAC7.html)
US20090269402A1 (en) Modified release composition of at least one form of venlafaxine
US20130323309A1 (en) Sustained Release Composition of Memantine
JP6461142B2 (ja) イソニアジドの顆粒およびリファペンチンの顆粒を含むコーティング錠の形態の抗結核性の安定な医薬組成物ならびにその製造方法
AU2017252407A1 (en) Oral pharmaceutical compositions of nicotinamide
US10258577B2 (en) Multilayer solid pharmaceutical dosage forms
KR20140045925A (ko) 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
US20150366850A1 (en) Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
JP2009542669A (ja) ピペリジノアルカノールと充血除去剤の組み合わせを含んで成る医薬組成物
CN104274387A (zh) 美托洛尔缓释组合物
US11147767B2 (en) Gastroretentive formulations
WO2011016057A2 (en) Controlled release pharmaceutical compositions of milnacipran
JP2013536832A (ja) ミルナシプランの制御放出医薬組成物